Injection possible cancer composition 机翻标题: 暂无翻译,请尝试点击翻译按钮。

源语言标题
(JP2015534951) 注射​可能​な​癌​組成​物
公开号/公开日
JP2015534951 A 2015-12-07 [JP2015534951] / 2015-12-07
申请号/申请日
2015JP-0536991 / 2013-10-14
发明人
;
申请人
JENSUPERA;
主分类号
IPC分类号
A61K-009/107A61K-031/365A61K-047/14A61K-047/24A61K-047/26A61K-047/42A61K-047/48A61P-035/00A61P-043/00C07K-007/00
摘要
(JP2015534951) Provided herein are therapeutic prodrug compositions which may be delivered to a patient via an injectable emulsion, comprising a therapeutic drug linked to a peptide that is efficiently and specifically cleaved by a selected protease associated with a cell proliferative disorder, including cancer cells, for example, prostate, liver or breast cancer cells, in a patient.  Also provided herein are methods of treating cell proliferative disorders, including cancers, with the therapeutic prodrug compositions.  (From US2015265572 A1)
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2012US-61714662 2012-10-16 2013WO-US64889 2013-10-14
主权利要求
(JP2015534951)  1. Being the medicine composition which is suited for the dosage inside the vein, (A) The sesquiterpene - the remedy active medicine which includes ***.gamma.-rakuton, that analog or the derivative and, The peptide which includes the amino acid arrangement which possesses the unique cutting region in the protease which it is related to the cell vegetating disease and, Being the professional drug which is included, Here, the said peptide has the amino acid length of 20 or less, the said peptide is connected by the remedy active medicine in order to obstruct the remedy activity of the medicine, the remedy active medicine is cut off to the case of the proteolysis by the said protease from the said peptide;  And (B) The vehicle which is allowed pharmacy;   It includes, the said professional drug approximately 1.5- of all composition approximately 2.5 weight % exists at the quantity, the medicine composition. 2. The description above pharmacy is allowed the vehicle which, Approximately 5- of all composition approximately 15 weight % the lecithin or the phosphatide of the quantity, and Approximately 8- of all composition approximately 17 weight % the sucrose of the quantity, It includes, the composition of claim 1 statement. 3. The description above pharmacy is allowed the vehicle which, Approximately 5 weight % to the oil of the quantity of all composition, and Approximately 5 weight % to the medium chain triglyceride of the quantity of all composition, Furthermore it includes, the composition of claim 2 statement. 4. The description above pharmacy is allowed the vehicle which, Approximately 0.5- of all composition approximately 3 weight % the oil of the quantity, Approximately 0.5- of all composition approximately 3 weight % the medium chain triglyceride of the quantity, Approximately 5- of all composition approximately 12 weight % the lecithin or the phosphatide of the quantity, and Approximately 10- of all composition approximately 15 weight % the sucrose of the quantity, It includes, the composition of claim 3 statement. 5. The description above pharmacy is allowed the vehicle which, Approximately 0.5- of all composition approximately 1 weight % the oil of the quantity, Approximately 0.5- of all composition approximately 1 weight % the medium chain triglyceride of the quantity, Approximately 5- of all composition approximately 10 weight % the lecithin or the phosphatide of the quantity, and Approximately 10- of all composition approximately 15 weight % the sucrose of the quantity, It includes, the composition of claim 4 statement. 6. The aforementioned professional drug exists approximately 2 weight % at the quantity of all composition, the composition of claim 5 statement. 7. Weight ratio of lecithin anti- professional drug approximately 5:1-7.5: 1 is, the composition of claim 2 statement. 8. Weight ratio of lecithin anti- professional drug approximately 5:1-7.5: 1 is, the composition of claim 3 statement. 9. Weight ratio of lecithin anti- oil approximately 10:1-5: 1 is, the composition of claim 3 statement. 10. Weight ratio of lecithin anti- oil approximately 10:1-5: 1 is, the composition of claim 8 statement. 11. The aforementioned professional drug includes, Ser-Ser-Lys-Tyr-Gln (arrangement number 18) the [tapushigarugin] derivative 8-O- which is connected to the [karubokishi] end of the peptide which includes arrangement (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 7 statement. 12. The aforementioned professional drug includes, Ser-Ser-Lys-Tyr-Gln (arrangement number 18) the [tapushigarugin] derivative 8-O- which is connected to the [karubokishi] end of the peptide which includes arrangement (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 10 statement. 13. Weight ratio of lecithin anti- professional drug approximately 2.5:1-5: 1 is, the composition of claim 2 statement. 14. Weight ratio of lecithin anti- professional drug approximately 2.5:1-5: 1 is, the composition of claim 3 statement. 15. Weight ratio of lecithin anti- oil approximately 10:1-5: 2 is, the composition of claim 3 statement. 16. Weight ratio of lecithin anti- oil approximately 10:1-5: 2 is, the composition of claim 14 statement. 17. The aforementioned professional drug includes, arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) the [tapushigarugin] derivative 8-O- which is connected to the aspartic acid of the peptide which it possesses (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 13 statement. 18. The aforementioned professional drug includes, arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) the [tapushigarugin] derivative 8-O- which is connected to the aspartic acid of the peptide which it possesses (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 16 statement. 19. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 2 statement. 20. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 3 statement. 21. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 2 statement. 22. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 3 statement. 23. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 19 statement. 24. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 20 statement. 25. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 10 statement. 26. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 10 statement. 27. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 25 statement. 28. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 16 statement. 29. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 16 statement. 30. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, the composition of claim 28 statement. 31. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 2 statement. 32. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 31 statement. 33. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 3 statement. 34. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 33 statement. 35. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, the composition of claim 2 statement. 36. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, the composition of claim 3 statement. 37. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, claim the composition of 32 or 34 statements. 38. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 10 statement. 39. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 38 statement. 40. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, the composition of claim 10 statement. 41. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, the composition of claim 39 statement. 42. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 16 statement. 43. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 42 statement. 44. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, the composition of claim 16 statement. 45. The guttulate of the aforementioned composition freezing - has the average diameter under approximately 200 nano- meters after the melting stress, the composition of claim 43 statement. 46. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 2 statement. 47. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 3 statement. 48. Approximately, the light transmittance value with 600nm of 60% or more is shown, claim the composition of 46 or 47 statements. 49. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 10 statement. 50. Approximately, the light transmittance value with 600nm of 60% or more is shown, the composition of claim 49 statement. 51. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 16 statement. 52. Approximately, the light transmittance value with 600nm of 60% or more is shown, the composition of claim 51 statement. 53. The aforementioned composition is freeze drying possible, the composition of claim 2 statement. 54. The aforementioned composition is freeze drying possible, the composition of claim 3 statement. 55. The aforementioned composition at least 3 months chemically is stability, claim the composition of 53 or 54 statements. 56. The aforementioned sesquiterpene - ***.gamma.-rakuton is the [tapushigarugin] or [tapushigarugin] derivative, the composition of claim 2 statement. 57. The aforementioned sesquiterpene - ***.gamma.-rakuton is the [tapushigarugin] or [tapushigarugin] derivative, the composition of claim 3 statement. 58. The [tapushigarugin] derivative is 8-O- (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), the composition of claim 56 statement. 59. The [tapushigarugin] derivative is 8-O- (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), the composition of claim 57 statement. 60. The [tapushigarugin] derivative is 8-O- (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 56 statement. 61. The [tapushigarugin] derivative is 8-O- (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 57 statement. 62. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 2 statement. 63. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 3 statement. 64. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 56 statement. 65. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 57 statement. 66. The aforementioned [tapushigarugin] derivative Ser-Ser-Lys-Tyr-Gln (arrangement number 18) is connected to the [karubokishi] end of the peptide which includes arrangement, the composition of claim 60 statement. 67. The aforementioned [tapushigarugin] derivative Ser-Ser-Lys-Tyr-Gln (arrangement number 18) is connected to the [karubokishi] end of the peptide which includes arrangement, the composition of claim 61 statement. 68. The aforementioned [tapushigarugin] derivative arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) is connected by the aspartic acid of the peptide which it possesses, here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 58 statement. 69. The aforementioned [tapushigarugin] derivative arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) is connected by the aspartic acid of the peptide which it possesses, here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 59 statement. 70. It is selected from the group where the lecithin consists of the soybean lecithin, the egg lecithin, or these combinations or that salt, the composition of claim 3 statement. 71. The aforementioned oil is the soybean oil, the composition of claim 3 statement. 72. The injection possible freezing protective agent or the antioxidant furthermore is contained, the composition of claim 3 statement. 73. The freezing protective agent is the sucrose, the antioxidant EDTA or is that salt, the composition of claim 72 statement. 74. The cell vegetating disease is the cancer, the composition of claim 2 statement. 75. When reconstructing by the water, the medicine composition which is suited for the dosage inside the vein is formed, being the freeze drying composition, (A) The sesquiterpene - the remedy active medicine which includes ***.gamma.-rakuton, that analog or the derivative and, The peptide which includes the amino acid arrangement which possesses the unique cutting region in the protease which it is related to the cell vegetating disease and, Being the professional drug which is included, Here, the said peptide has the amino acid length of 20 or less, the said peptide is connected by the remedy active medicine in order to obstruct the remedy activity of the medicine, the remedy active medicine is cut off to the case of the proteolysis by the said protease from the said peptide;  And (B) The vehicle which is allowed pharmacy;   It includes, the said professional drug approximately 1.5- of all composition approximately 2.5 weight % exists at the quantity, the composition. 76. The description above pharmacy is allowed the vehicle which, Approximately 5- of all composition approximately 15 weight % the lecithin or the phosphatide of the quantity, and Approximately 8- of all composition approximately 17 weight % the sucrose of the quantity, It includes, the composition of claim 75 statement. 77. The description above pharmacy is allowed the vehicle which, Approximately 5 weight % to the oil of the quantity of all composition, and Approximately 5 weight % to the medium chain triglyceride of the quantity of all composition, Furthermore it includes, the composition of claim 76 statement. 78. The description above pharmacy is allowed the vehicle which, Approximately 0.5- of all composition approximately 3 weight % the oil of the quantity, Approximately 0.5- of all composition approximately 3 weight % the medium chain triglyceride of the quantity, Approximately 5- of all composition approximately 12 weight % the lecithin or the phosphatide of the quantity, and Approximately 10- of all composition approximately 15 weight % the sucrose of the quantity, It includes, the composition of claim 77 statement. 79. The description above pharmacy is allowed the vehicle which, Approximately 0.5- of all composition approximately 1 weight % the oil of the quantity, Approximately 0.5- of all composition approximately 1 weight % the medium chain triglyceride of the quantity, Approximately 5- of all composition approximately 10 weight % the lecithin or the phosphatide of the quantity, and Approximately 10- of all composition approximately 15 weight % the sucrose of the quantity, It includes, the composition of claim 78 statement. 80. The aforementioned professional drug exists approximately 2 weight % at the quantity of all composition, the composition of claim 79 statement. 81. Weight ratio of lecithin anti- professional drug approximately 5:1-7.5: 1 is, the composition of claim 76 statement. 82. Weight ratio of lecithin anti- professional drug approximately 5:1-7.5: 1 is, the composition of claim 77 statement. 83. Weight ratio of lecithin anti- oil approximately 10:1-5: 1 is, the composition of claim 77 statement. 84. Weight ratio of lecithin anti- oil approximately 10:1-5: 1 is, the composition of claim 82 statement. 85. The aforementioned professional drug includes, Ser-Ser-Lys-Tyr-Gln (arrangement number 18) the [tapushigarugin] derivative 8-O- which is connected to the [karubokishi] end of the peptide which includes arrangement (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 81 statement. 86. The aforementioned professional drug includes, Ser-Ser-Lys-Tyr-Gln (arrangement number 18) the [tapushigarugin] derivative 8-O- which is connected to the [karubokishi] end of the peptide which includes arrangement (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 82 statement. 87. Weight ratio of lecithin anti- professional drug approximately 2.5:1-5: 1 is, the composition of claim 76 statement. 88. Weight ratio of lecithin anti- professional drug approximately 2.5:1-5: 1 is, the composition of claim 77 statement. 89. Weight ratio of lecithin anti- oil approximately 10:1-5: 2 is, the composition of claim 77 statement. 90. Weight ratio of lecithin anti- oil approximately 10:1-5: 2 is, the composition of claim 88 statement. 91. The aforementioned professional drug includes, arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) the [tapushigarugin] derivative 8-O- which is connected to the aspartic acid of the peptide which it possesses (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 88 statement. 92. The aforementioned professional drug includes, arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) the [tapushigarugin] derivative 8-O- which is connected to the aspartic acid of the peptide which it possesses (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 90 statement. 93. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 76 statement. 94. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 77 statement. 95. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 84 statement. 96. The aforementioned composition, it is possible to filter through 0.2 micron filter the composition of claim 90 statement. 97. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 76 statement. 98. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 97 statement. 99. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 77 statement. 100. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 99 statement. 101. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 84 statement. 102. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 101 statement. 103. The guttulate of the aforementioned composition has the average diameter under approximately 200 nano- meters, the composition of claim 90 statement. 104. The guttulate of the aforementioned composition has the average diameter under approximately 150 nano- meters, the composition of claim 103 statement. 105. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 76 statement. 106. Approximately, the light transmittance value with 600nm of 60% or more is shown, the composition of claim 105 statement. 107. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 77 statement. 108. Approximately, the light transmittance value with 600nm of 60% or more is shown, the composition of claim 107 statement. 109. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 84 statement. 110. Approximately, the light transmittance value with 600nm of 60% or more is shown, the composition of claim 109 statement. 111. Approximately, the light transmittance value with 600nm of 30% or more is shown, the composition of claim 90 statement. 112. Approximately, the light transmittance value with 600nm of 60% or more is shown, the composition of claim 111 statement. 113. The aforementioned composition at least 3 months chemically is stability, the composition of claim 76 statement. 114. The aforementioned composition at least 3 months chemically is stability, the composition of claim 77 statement. 115. The aforementioned sesquiterpene - ***.gamma.-rakuton is the [tapushigarugin] or [tapushigarugin] derivative, the composition of claim 76 statement. 116. The aforementioned sesquiterpene - ***.gamma.-rakuton is the [tapushigarugin] or [tapushigarugin] derivative, the composition of claim 77 statement. 117. The [tapushigarugin] derivative is 8-O- (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), the composition of claim 115 statement. 118. The [tapushigarugin] derivative is 8-O- (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), the composition of claim 116 statement. 119. The [tapushigarugin] derivative is 8-O- (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 115 statement. 120. The [tapushigarugin] derivative is 8-O- (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), the composition of claim 116 statement. 121. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 76 statement. 122. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 77 statement. 123. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 115 statement. 124. The aforementioned peptide, the enzyme which possesses the proteolysis activity of protease or PSA, PSMA, hK2 or FAP which are selected, includes the amino acid arrangement which possesses the unique cutting region from the group which consists of PSA, PSMA, hK2 and FAP, the composition of claim 116 statement. 125. The aforementioned [tapushigarugin] derivative Ser-Ser-Lys-Tyr-Gln (arrangement number 18) is connected to the [karubokishi] end of the peptide which includes arrangement, the composition of claim 119 statement. 126. The aforementioned [tapushigarugin] derivative Ser-Ser-Lys-Tyr-Gln (arrangement number 18) is connected to the [karubokishi] end of the peptide which includes arrangement, the composition of claim 120 statement. 127. The aforementioned [tapushigarugin] derivative arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) is connected by the aspartic acid of the peptide which it possesses, here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 117 statement. 128. The aforementioned [tapushigarugin] derivative arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) is connected by the aspartic acid of the peptide which it possesses, here, at least one of the connection which is appointed * by is I [karubokishi] connection, the composition of claim 118 statement. 129. It is selected from the group where the lecithin consists of the soybean lecithin, the egg lecithin, or these combinations or that salt, the composition of claim 77 statement. 130. The aforementioned oil is the soybean oil, the composition of claim 77 statement. 131. The injection possible freezing protective agent or the antioxidant furthermore is contained, the composition of claim 77 statement. 132. The freezing protective agent is the sucrose, the antioxidant EDTA or is that salt, the composition of claim 131 statement. 133. Being the method of manufacturing the medicine composition, process below: (A) The process which mixes the composition of claim 2 statement with the water, (B) The process which homogenizes the said blend to the average liquid drop size under diameter 200nm, (C) The process which makes 0.2 micron filter pass, The method of including. 134. Being the method of manufacturing the medicine composition, process below: (A) The process which mixes the composition of claim 3 statement with the water, (B) The process which homogenizes the said blend to the average liquid drop size under diameter 200nm, (C) The process which makes 0.2 micron filter pass, The method of including. 135. Average liquid drop size is under diameter 150nm, method of claim 133 statement. 136. Average liquid drop size is under diameter 150nm, method of claim 134 statement. 137. Weight ratio of lecithin anti- professional drug approximately 5:1-7.5: 1 is, method of claim 133 statement. 138. Weight ratio of lecithin anti- professional drug approximately 5:1-7.5: 1 is, method of claim 134 statement. 139. Weight ratio of lecithin anti- oil approximately 10:1-5: 1 is, method of claim 134 statement. 140. Weight ratio of lecithin anti- oil approximately 10:1-5: 1 is, method of claim 138 statement. 141. The aforementioned professional drug includes, Ser-Ser-Lys-Tyr-Gln (arrangement number 18) the [tapushigarugin] derivative 8-O- which is connected to the [karubokishi] end of the peptide which includes arrangement (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), method of claim 137 statement. 142. The aforementioned professional drug includes, Ser-Ser-Lys-Tyr-Gln (arrangement number 18) the [tapushigarugin] derivative 8-O- which is connected to the [karubokishi] end of the peptide which includes arrangement (12- [[L]-roishinoiruamino] [dodekanoiru]) - ***8-O-debutanoirutapushigarugin (L12ADT), method of claim 140 statement. 143. Weight ratio of lecithin anti- professional drug approximately 2.5:1-5: 1 is, method of claim 133 statement. 144. Weight ratio of lecithin anti- professional drug approximately 2.5:1-5: 1 is, method of claim 134 statement. 145. Weight ratio of lecithin anti- oil approximately 10:1-5: 2 is, method of claim 134 statement. 146. Weight ratio of lecithin anti- oil approximately 10:1-5: 2 is, method of claim 144 statement. 147. The aforementioned professional drug includes, arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) the [tapushigarugin] derivative 8-O- which is connected to the aspartic acid of the peptide which it possesses (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), here, at least one of the connection which is appointed * by is I [karubokishi] connection, method of claim 143 statement. 148. The aforementioned professional drug includes, arrangement Asp-Glu*Glu*Glu*Glu (arrangement number 486) the [tapushigarugin] derivative 8-O- which is connected to the aspartic acid of the peptide which it possesses (12 - [aminododekanoiru]) - ***8-O-debutanoirutapushigarugin (12ADT), here, at least one of the connection which is appointed * by is I [karubokishi] connection, method of claim 146 statement. 149. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, method of claim 133 statement. 150. The aforementioned composition freezing - can filter after the melting stress through 0.2 micron filter, method of claim 134 sta(...)
法律状态
(JP2015534951) LEGAL DETAILS FOR JP2015534951  Actual or expected expiration date=2033-10-14    Legal state=ALIVE    Status=PENDING     Event publication date=2013-10-14  Event code=JP/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=JP JP2015536991  Application date=2013-10-14  Standardized application number=2015JP-0536991     Event publication date=2015-10-28  Event code=JP/RD01  Event type=Change of name or address  Event type=Administrative notifications  Notification of change of attorney  Effective date of the event=2015-10-28  JAPANESE INTERMEDIATE CODE: A7426     Event publication date=2015-10-28  Event code=JP/RD01  Event type=Change of name or address  Event type=Administrative notifications  Notification of change of attorney  Effective date of the event=2015-10-28  JAPANESE INTERMEDIATE CODE: A7426     Event publication date=2015-11-16  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2015-10-28  JAPANESE INTERMEDIATE CODE: A821     Event publication date=2015-11-16  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2015-10-28  JAPANESE INTERMEDIATE CODE: A821     Event publication date=2015-12-07  Event code=JP/A  Event indicator=Pos  Event type=Examination events  Published application  Publication country=JP  Publication number=JP2015534951  Publication stage Code=A  Publication date=2015-12-07  Standardized publication number=JP2015534951     Event publication date=2016-10-12  Event code=JP/A521  Event type=Restitution or restoration  Written amendment  Effective date of the event=2016-10-12  JAPANESE INTERMEDIATE CODE: A523     Event publication date=2016-10-12  Event code=JP/A621  Event indicator=Pos  Event type=Examination events  Written request for application examination  Effective date of the event=2016-10-12  JAPANESE INTERMEDIATE CODE: A621
专利类型码
A
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部